Echinomycin (NSC 526417) in Squamous-Cell Carcinoma of the Cervix: A Phase II Trial of the Gynecologic Oncology Group
Abstract
Twenty-eight evaluable patients with advanced or recurrent squamous-cell carcinoma of the cervix were treated with 1,500 micrograms/m2 of echinomycin every 4 weeks. All patients had prior chemotherapy. Two patients had partial responses (7% response, 95% confidence interval for response of 1 to 24%). The major toxicity was nausea and vomiting. Myelosuppression and other toxicity were modest. Echinomycin, at this dose and schedule, displays minimal activity in patients with squamous-cell carcinoma of the cervix who have had prior chemotherapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical studies have provided considerable safety data for echinomycin.
“Clinical studies have provided considerable safety data for echinomycin10-12, 14-18, 41-45”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [41]
Cited by
Sorted by citations
Targeting HIF1α Eliminates Cancer Stem Cells in Hematological Malignancies
Wang, Y., Liu, Y., Malek, S. N., Zheng, P., & Liu, Y. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.02.006 · Cited by 410 · see citing works
“Remarkably, based on per square meter of body surface, echinomycin at doses that are nearly 50-fold higher than what was used in this study, were well tolerated in human (Muss et al., 1990), although the impact of the drug on CSC was not evaluated because these trials predated the reemergence of CSC concept (Lapidot e…”
Dawson, S. J., Malkinson, J. P., Paumier, D., & Searcey, M. (2006) · Natural Product Reports · doi:10.1039/b516347c · Cited by 99 · see citing works
The Role of Chemotherapy in the Management of Carcinoma of the Cervix
Thigpen, T. (2003) · The Cancer Journal · doi:10.1097/00130404-200309000-00013 · Cited by 56 · see citing works
Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · see citing works
Sayers, E. W., & Waring, M. J. (1993) · Biochemistry · doi:10.1021/bi00086a014 · Cited by 36 · see citing works
Targeting Cancer Stem Cells with Natural Products
Burnett, J., Newman, B. W., & Sun, D. (2012) · Current Drug Targets · doi:10.2174/138945012802009062 · Cited by 33 · see citing works
Echinomycin and Related Quinoxaline Antibiotics
Waring, M. J. (1993) · doi:10.1007/978-1-349-12356-8_7 · Cited by 19 · see citing works
Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix
Muss, H. B., Blessing, J. A., Eddy, G. L., & McGehee, R. (1992) · Investigational New Drugs · doi:10.1007/bf01275474 · Cited by 8 · see citing works
“A similar t r ia l done by the G O G , using the same ech inomyc in dose and schedule in pat ients who had p r io r chemothera py resul ted in two par t i a l responses in 28 evaluable pat ients (7%) [6].”
MethodSelf-citationXu, L., Ishikawa, H., Zhou, Y., Kobayashi, T., & Shozu, M. (2022) · F&S Science · doi:10.1016/j.xfss.2022.01.005 · Cited by 6 · see citing works
Petersen, M. E., Brant, M. G., Lasalle, M., Fung, V., Rojas, A. H., Wong, J., Das, S., Barnscher, S. D., Rich, J. R., & Winters, G. C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00760 · Cited by 5 · see citing works
Chemotherapy for advanced or recurrent carcinoma of the cervix
Bloss, J. D. (2001) · Current Oncology Reports · doi:10.1007/s11912-001-0040-5 · Cited by 2 · see citing works
- Authors
- Muss, H. B., Blessing, J. A., & Malfetano, J.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- ORCID
- Muss, Hyman B.
- Venue
- American Journal of Clinical Oncology
- Published
- 1990-06
- Volume
- 13
- Issue
- 3
- Pages
- 191-193
- ISSN
- 0277-3732 (ISSN-L)
- OpenAlex
- W2061913371
- Cited by
- 11
- References
- 0
- Citations by year
- 2023: 1 · 2022: 1 · 2020: 1 · 2012: 1
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 23088, CA-27816, CA23501)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- echinomycin, cervical squamous cell carcinoma, recurrent cervical cancer, advanced cervical cancer, topoisomerase I inhibitor, chemotherapy toxicity, myelosuppression, nausea and vomiting, prior chemotherapy
- MeSH terms
- Adult, Aged, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Drug Evaluation, Echinomycin, Female, Humans, Middle Aged, Nausea, Neoplasm Metastasis, Neoplasm Recurrence, Local, Quinoxalines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
